Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772333 | 1.00 | NFE2L2 (0.52) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL1144907 | 0.98 | NFE2L2 (0.50) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL1144905 | 0.98 | NFE2L2 (0.50) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL2647678 | 0.84 | NFE2L2 (0.44) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL1219862 | 0.84 | RECQL (0.57) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL7916953 | 0.84 | NFE2L2 (0.44) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL1219859 | 0.84 | RECQL (0.57) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL2647676 | 0.84 | NFE2L2 (0.44) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL16807839 | 0.78 | NFE2L2 (0.39) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL16807843 | 0.78 | NFE2L2 (0.39) | NFE2L2HCAR2KEAP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3444251-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3080122-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| EP-3080122-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-6680319-B2 | TREATMENT OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA, TREATMENT OF LOWER URINARY TRACT SYMPTOMS | RECORDATI S.A. (CH) | 2004-01-20 | — | — | US | disclosed |
| EP-1226131-B1 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-12-17 | — | — | EP | disclosed |
| EP-1226131-A2 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-07-31 | — | — | EP | disclosed |
| US-6365591-B1 | FOR THERAPY OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA (BPH), AND IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND NEUROGENIC LOWER URINARY TRACT DYSFUNCTION (NLUTD) | RECORDATI, S.A., CHEMICAL AND PHARMACUETICALS COMPANY (CH) | 2002-04-02 | — | — | US | disclosed |
| WO-2001029015-A2 | ISOXAZOLECARBOXAMIDE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2001-04-26 | — | — | WO | disclosed |
| EP-0638074-B1 | ISOXAZOLE CARBOXYLIC ACID AMIDES, PROCESS FOR PRODUCING THEM AND THEIR USE | BASF AG (DE) | 1999-03-31 | — | — | EP | disclosed |
| US-5576270-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-19 | — | — | US | disclosed |
| EP-0638074-A1 | ISOXAZOLE CARBOXYLIC ACID AMIDES, PROCESS FOR PRODUCING THEM AND THEIR USE | BASF Aktiengesellschaft (DE) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993022295-A1 | ISOXAZOLE CARBOXYLIC ACID AMIDES, PROCESS FOR PRODUCING THEM AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-11 | — | — | WO | disclosed |
| EP-0176846-B1 | 3-AMINO-2-BENZOYL-ACRYLIC-ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1989-08-16 | — | — | EP | disclosed |
| US-4699992-A | 3-amino-2-benzoylacrylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| EP-0176846-A2 | 3-Amino-2-benzoyl-acrylic-acid derivatives and process for their preparation | BAYER AG (DE) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | NFE2L2 3583/4885HCAR2 4064/4885KEAP1 2090/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | NFE2L2 3583/4885HCAR2 4064/4885KEAP1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.